Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
DEA proposes placing tianeptine in Schedule I, making it illegal to manufacture, distribute, or possess without authorization. This affects any business handling tianeptine, including API manufacturers, compounders, and researchers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that handle tianeptine or its isomers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date of final rule (typically 30 days after publication in Federal Register); comments due by August 7, 2026.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Tianeptine is proposed to be classified as a Schedule I controlled substance, with no currently accepted medical use and high abuse potential.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities that handle tianeptine or its isomers.
What you must do
Cease all manufacturing, distribution, and dispensing of tianeptine immediately upon final rule; surrender any existing stocks to DEA; cancel any pending applications or quotas.
Deadline
Effective date of final rule (typically 30 days after publication in Federal Register); comments due by August 7, 2026.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness